The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data.
{"title":"The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data.","authors":"Fuxun Zhang, Zhirong Luo, Qi Xue, Xuyan Guo, Qiang Fu, Yong Jiao, Wei Zhang, Yang Xiong, Pati-Alam Alisha, Uzoamaka Adaobi Okoli, Geng Zhang","doi":"10.1080/14737140.2025.2522981","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer (mHSPC) across different disease volumes remains uncertain. This meta-analysis aims to clarify benefit of abiraterone in low- and high-volume subgroups using full analysis set and reconstructed individual patient data (IPD).</p><p><strong>Research design and methods: </strong>Phase III randomized clinical trials of abiraterone were selected. IPD for overall survival (OS), progression-free survival (PFS), and cancer-specific survival were reconstructed. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to assess the efficacy, and risk ratios (RRs) with 95% CIs were used to summarized adverse events. Survival analysis was performed using Cox hazards model based on the reconstructed IPD. Heterogeneity was assessed by Cochran's Q and I<sup>2</sup>.</p><p><strong>Results: </strong>Data for 3182 patients were analyzed. In the overall population, abiraterone improved OS (HR: 0.66, 95% CI 0.59-0.73) and PFS (HR: 0.51, 95% CI 0.45-0.58). Subgroup analyses showed consistent OS benefit of abiraterone across low- and high-volume subgroups (HR: 0.71 and 0.64), and PFS benefit in counterparts (HR: 0.49 and 0.46). Grade 1-2 adverse events were reduced in abiraterone group (RR 0.66), while grade 3-4 events increased (RR 1.33). Heterogeneity was low except for PFS in low-volume subgroup. The Kaplan-Meier curves showed that abiraterone significantly improved OS and PFS across all subgroups (All <i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Adding abiraterone provided significant survival benefits in patients with mHSPC regardless of disease volume. Future investigation should aim to drive more personalized therapies and validate these findings in real world setting.</p><p><strong>Registration: </strong>PROSPERO: ;(CRD420251028079).</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2522981","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer (mHSPC) across different disease volumes remains uncertain. This meta-analysis aims to clarify benefit of abiraterone in low- and high-volume subgroups using full analysis set and reconstructed individual patient data (IPD).
Research design and methods: Phase III randomized clinical trials of abiraterone were selected. IPD for overall survival (OS), progression-free survival (PFS), and cancer-specific survival were reconstructed. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to assess the efficacy, and risk ratios (RRs) with 95% CIs were used to summarized adverse events. Survival analysis was performed using Cox hazards model based on the reconstructed IPD. Heterogeneity was assessed by Cochran's Q and I2.
Results: Data for 3182 patients were analyzed. In the overall population, abiraterone improved OS (HR: 0.66, 95% CI 0.59-0.73) and PFS (HR: 0.51, 95% CI 0.45-0.58). Subgroup analyses showed consistent OS benefit of abiraterone across low- and high-volume subgroups (HR: 0.71 and 0.64), and PFS benefit in counterparts (HR: 0.49 and 0.46). Grade 1-2 adverse events were reduced in abiraterone group (RR 0.66), while grade 3-4 events increased (RR 1.33). Heterogeneity was low except for PFS in low-volume subgroup. The Kaplan-Meier curves showed that abiraterone significantly improved OS and PFS across all subgroups (All p < 0.05).
Conclusions: Adding abiraterone provided significant survival benefits in patients with mHSPC regardless of disease volume. Future investigation should aim to drive more personalized therapies and validate these findings in real world setting.
期刊介绍：
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
